BridgeBio Oncology Therapeutics: Recent News Overview (November 2025)
BridgeBio Oncology Therapeutics (BBOT), previously a subsidiary of BridgeBio Pharma, is advancing a next-generation pipeline of small molecule therapeutics targeting RAS and PI3Kα-driven cancers1.
A business combination between BBOT (d/b/a TheRas, Inc.) and Helix Acquisition Corp II (Nasdaq:
HLXB) is proceeding, retaining over 60% of Helix's trust account post-redemptions—about $120 million, with the aggregate transaction expected to raise approximately $382 million, including $261 million in PIPE financing led by large institutional investors1.
This transaction recorded the 2nd lowest redemption rate among biotech de-SPAC deals since 2022, underpinning notable investor support for BBOT’s oncology pipeline1.
BBOT focuses on precision oncology solutions, especially inhibiting active RAS signaling, with programs spanning broad KRAS mutant targeting and selective inhibition of RAS-driven PI3K activation6.
BBOT announced multiple presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, highlighting continued R&D activities and scientific engagement9.
The latest financial results (covering third quarter and first nine months of 2025) were published and are accessible, reflecting ongoing corporate transparency and milestone achievement reporting11.
Sources:
1. https://www.globenewswire.com/news-release/2025/08/06/3128242/0/en/Helix-Acquisition-Corp-II-Retains-More-than-60-of-Trust-Account-after-Redemptions-in-connection-with-Business-Combination-with-BridgeBio-Oncology-Therapeutics.html
9. https://www.nasdaq.com/market-activity/stocks/bbot/press-releases
11. https://www.zonebourse.com/actualite-bourse/bridgebio-oncology-therapeutics-inc-resultats-financiers-du-troisieme-trimestre-et-des-neuf-prem-ce7d5fdddd80f42c